He is the CSO of the biotech company Kariya Pharmaceuticals Ltd
CBC, lipid, thyroid & full panels
After a dose-titration and dose-stable run-in period of up to 16 weeks and a 2-week placebo run-in period, patients with inadequate glycemic control (A1C 7.5% to 10.5%) were randomized to the addition of either 100 mg of JANUVIA or placebo, administered once daily
Seth Carpenter: What about the growth risks to the euro area
Across the nine-month follow-up period, 60 percent of patients treated with mavacamten monotherapy improved by at least one Co-author Garima Arora, M.D., co-director of the UAB Cardiogenomics Clinic, emphasized the practice-changing implications
Not enough is known about the use of L-Carnitine during pregnancy and breast-feeding